Dietary supplements in people with metastatic cancer who are experiencing malnutrition, cachexia, sarcopenia, and frailty : a scoping review
- Johal, Jolyn, Han, Chad, Joseph, Ria, Munn, Zachary, Agbejule, Oluwaseyifunmi, Crawford‐Williams, Fiona, Wallen, Matthew, Chan, Raymond, Hart, Nicolas
- Authors: Johal, Jolyn , Han, Chad , Joseph, Ria , Munn, Zachary , Agbejule, Oluwaseyifunmi , Crawford‐Williams, Fiona , Wallen, Matthew , Chan, Raymond , Hart, Nicolas
- Date: 2022
- Type: Text , Journal article , Review
- Relation: Nutrients Vol. 14, no. 13 (2022), p.
- Full Text:
- Reviewed:
- Description: Cancer‐associated malnutrition, or cachexia, stemming from cancer or its treatments, is particularly prevalent in metastatic cancers, and is often interrelated with sarcopenia and frailty. Evidence suggests that dietary supplements play a role in managing these conditions. As metastatic cancer cells are associated with notable genomic and phenotypic alterations, response to dietary supplements may differ between metastatic and non‐metastatic cancers. However, research in this area is lacking. This scoping review aims to identify the dietary supplements that have been studied in patients with metastatic cancers and malnutrition‐related conditions, along with their proposed effects, mechanisms, outcome measures, and tools used. A systematic search was conducted across databases, including MEDLINE, EMBASE, CINAHL, and clinical trial registries. Of the initial 6535 records screened, a total of 48 studies were included, covering a range of dietary supplements— vitamins, minerals, antioxidants, proteins, amino acids, fatty acids, fiber, and others. While the types of dietary supplements included varied across cancer types, omega‐3 and carnitine were investigated most often. Proposed relevant attributes of dietary supplements included their antioxidant, anti‐inflammatory, anti‐cancer, and immunomodulatory properties. Overall, there was a paucity of interventional studies, and more randomized controlled trials are warranted. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
- Authors: Johal, Jolyn , Han, Chad , Joseph, Ria , Munn, Zachary , Agbejule, Oluwaseyifunmi , Crawford‐Williams, Fiona , Wallen, Matthew , Chan, Raymond , Hart, Nicolas
- Date: 2022
- Type: Text , Journal article , Review
- Relation: Nutrients Vol. 14, no. 13 (2022), p.
- Full Text:
- Reviewed:
- Description: Cancer‐associated malnutrition, or cachexia, stemming from cancer or its treatments, is particularly prevalent in metastatic cancers, and is often interrelated with sarcopenia and frailty. Evidence suggests that dietary supplements play a role in managing these conditions. As metastatic cancer cells are associated with notable genomic and phenotypic alterations, response to dietary supplements may differ between metastatic and non‐metastatic cancers. However, research in this area is lacking. This scoping review aims to identify the dietary supplements that have been studied in patients with metastatic cancers and malnutrition‐related conditions, along with their proposed effects, mechanisms, outcome measures, and tools used. A systematic search was conducted across databases, including MEDLINE, EMBASE, CINAHL, and clinical trial registries. Of the initial 6535 records screened, a total of 48 studies were included, covering a range of dietary supplements— vitamins, minerals, antioxidants, proteins, amino acids, fatty acids, fiber, and others. While the types of dietary supplements included varied across cancer types, omega‐3 and carnitine were investigated most often. Proposed relevant attributes of dietary supplements included their antioxidant, anti‐inflammatory, anti‐cancer, and immunomodulatory properties. Overall, there was a paucity of interventional studies, and more randomized controlled trials are warranted. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Patient navigation across the cancer care continuum : an overview of systematic reviews and emerging literature
- Chan, Raymond, Milch, Vivienne, Crawford-Williams, Fiona, Agbejule, Oluwaseyifunmi, Joseph, Ria, Johal, Jolyn, Dick, Narayanee, Wallen, Matthew, Ratcliffe, Julie, Agarwal, Anupriya, Nekhlyudov, Larissa, Tieu, Matthew, Al-Momani, Manaf, Turnbull, Scott, Sathiaraj, Rahul, Keefe, Dorothy, Hart, Nicholas
- Authors: Chan, Raymond , Milch, Vivienne , Crawford-Williams, Fiona , Agbejule, Oluwaseyifunmi , Joseph, Ria , Johal, Jolyn , Dick, Narayanee , Wallen, Matthew , Ratcliffe, Julie , Agarwal, Anupriya , Nekhlyudov, Larissa , Tieu, Matthew , Al-Momani, Manaf , Turnbull, Scott , Sathiaraj, Rahul , Keefe, Dorothy , Hart, Nicholas
- Date: 2023
- Type: Text , Journal article , Review
- Relation: CA Cancer Journal for Clinicians Vol. 73, no. 6 (2023), p. 565-589
- Relation: http://purl.org/au-research/grants/nhmrc/1194051
- Full Text:
- Reviewed:
- Description: Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. © 2023 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.
- Authors: Chan, Raymond , Milch, Vivienne , Crawford-Williams, Fiona , Agbejule, Oluwaseyifunmi , Joseph, Ria , Johal, Jolyn , Dick, Narayanee , Wallen, Matthew , Ratcliffe, Julie , Agarwal, Anupriya , Nekhlyudov, Larissa , Tieu, Matthew , Al-Momani, Manaf , Turnbull, Scott , Sathiaraj, Rahul , Keefe, Dorothy , Hart, Nicholas
- Date: 2023
- Type: Text , Journal article , Review
- Relation: CA Cancer Journal for Clinicians Vol. 73, no. 6 (2023), p. 565-589
- Relation: http://purl.org/au-research/grants/nhmrc/1194051
- Full Text:
- Reviewed:
- Description: Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. © 2023 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.
- «
- ‹
- 1
- ›
- »